Which Big Pharma Has the Busiest BD Team? You Might Be Surprised in this Part 2 for Q3

Which big pharma had the busiest M&A team? Q3 biopharma deal analysis

DealForma’s analysis, cited by John Carroll, shows Eli Lilly led big pharma in licensing deal activity for Q3 2025, followed by Novartis, Roche, Novo Nordisk, and AstraZeneca. Read it here

DealForma Research

Explore More
Biopharma Therapeutics and Platform IPOs Follow-on and PIPE Issuances - Q3 2025 Review

Biopharma Therapeutics and Platform IPOs Follow-on and PIPE Issuances – Q3 2025 Review

Biopharma Therapeutics and Platform Venture Funding - Q3 2025 Review

Biopharma Therapeutics and Platform Venture Funding – Q3 2025 Review

Biopharma Therapeutics and Platforms M&A – Q3 2025 Review

Biopharma Therapeutics and Platform M&A – Q3 2025 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive